These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34524212)

  • 1. Treatment with angiotensin receptor neprilysin inhibitor for Taiwan heart failure patients: Rationale and baseline characteristics of the TAROT-HF study.
    Lin WY; Chung FP; Liao CT; Huang JL; Liang HW; Lee YH; Lin PL; Chiou WR; Hsu CY; Chang HY
    J Chin Med Assoc; 2021 Sep; 84(9):833-841. PubMed ID: 34524212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia.
    Badreldin HA; Korayem GB; Alenazy BA; Aljohani MH; Alshaya OA; Al Sulaiman K; Alabdelmuhsin L; Alenazi H; Almutairi DM; Alanazi F; Alobathani SK; Alqannam GM; Almadani O; Aljuhani O; Hafiz A; Aljowaie G; Basha E; Alqahtani T; Alhussein M
    Medicine (Baltimore); 2023 Dec; 102(51):e36699. PubMed ID: 38134075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of sacubitril/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study.
    Zeymer U; Groves R; Hupfer S
    Herz; 2024 Oct; 49(5):385-392. PubMed ID: 38656397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study.
    Houchen E; Loefroth E; Schlienger R; Proudfoot C; Corda S; Saha S; Satwase SK; Studer R
    Cardiol Ther; 2022 Mar; 11(1):113-127. PubMed ID: 35094306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
    Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
    Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    Nordberg Backelin C; Fu M; Ljungman C
    ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients.
    Cheang I; Shi S; Lu X; Liao S; Zhu X; Su X; Lu Q; Yuan J; Xu D; Zhang M; Dai C; Wang J; Yuan F; Zhao Y; Zhou J; Li X
    J Cardiovasc Transl Res; 2022 Oct; 15(5):1192-1202. PubMed ID: 35505156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
    Visco V; Radano I; Campanile A; Ravera A; Silverio A; Masarone D; Pacileo G; Correale M; Mazzeo P; Dattilo G; Giallauria F; Cuomo A; Mercurio V; Tocchetti CG; Di Pietro P; Carrizzo A; Citro R; Galasso G; Vecchione C; Ciccarelli M
    ESC Heart Fail; 2022 Oct; 9(5):2909-2917. PubMed ID: 35702942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bridging the STRONG Gap: Call to Optimize Heart Failure Treatment After Hospitalization in Women and Men in Taiwan.
    Chang TW; Hung CL; Ko SL; Liao CT; Hsu CY; Huang N; Mebazaa A; Chang HY
    Am J Cardiol; 2024 Jul; 223():52-57. PubMed ID: 38763384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Characteristics and Outcomes of Patients with Heart Failure and Reduced Ejection Fraction: The Eligibility of Novel Heart Failure Medications.
    Fong MC; Chang HY; Wang CC; Feng AN; Lin WS; Wu YW; Sung SH; Huang JL; Kuo JY; Yin WH
    Acta Cardiol Sin; 2021 Jul; 37(4):394-403. PubMed ID: 34257489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.
    Chen X; Schaufelberger M; Fu M
    J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):6-12. PubMed ID: 31789711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.
    Wachter R; Fonseca AF; Balas B; Kap E; Engelhard J; Schlienger R; Klebs S; Wirta SB; Kostev K
    Eur J Heart Fail; 2019 May; 21(5):588-597. PubMed ID: 30972918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Angiotensin-Neprilysin Inhibition in Canines with Experimentally Induced Cardiorenal Syndrome.
    Sabbah HN; Zhang K; Gupta RC; Xu J; Singh-Gupta V
    J Card Fail; 2020 Nov; 26(11):987-997. PubMed ID: 32841710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
    Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
    J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.